NEW YORK (GenomeWeb) – Danaher today announced a definitive merger agreement to purchase Pall in an all-cash deal totaling approximately $13.8 billion. 

Under the terms of the deal, which is expected to be completed around the end of the year, Danaher will pay $127.20 for each share of Pall's stock. The $13.8 billion price tag includes assumed debt and is net of acquired cash. The boards of Danaher and Pall have unanimously approved the merger. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.